Clinical Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rusch, V.
Right arrow Articles by Dmitrovsky, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rusch, V.
Right arrow Articles by Dmitrovsky, E.

Clinical Cancer Research, Vol 3, Issue 4 515-522, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

V Rusch, D Klimstra, E Venkatraman, PW Pisters, J Langenfeld and E Dmitrovsky
Division of Thoracic Surgery, Department of Surgery, Molecular Medicine, Department of Medicine, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

The epidermal growth factor receptor (EGFR) and its ligand transforming growth factor (TGF) alpha are hypothesized to form an autocrine growth loop in non-small cell lung cancer (NSCLC) and to play an important role in tumor formation and progression. We studied the association between overexpression of EGFR, TGF-alpha, or both, and overall survival of patients with resectable NSCLC. Overexpression, defined as >20% of tumor cells staining on immunohistochemistry, was examined in 96 tumor samples from consecutive patients having resection of previously untreated, well-staged NSCLC who were then followed prospectively (median follow-up, 20.7 months). The expression of three other ligands for EGFR (epidermal growth factor, cripto, and amphiregulin) was examined by Northern analysis to determine whether they might also contribute to a potential growth stimulatory loop. Overall, survival was calculated by the method of Kaplan and Meier, and prognostic factors were compared using the log-rank test. Overexpression of EGFR only was found in 32% (31 of 96), of TGF-alpha only in 10% (10 of 96), of both EGFR and TGF-alpha in 38% (37 of 96), and of neither in 19% (19 of 96) of tumors. EGFR and TGF-alpha overexpression was observed in all tumor stages and histological types but was most frequent in squamous cell carcinoma. By univariate and multivariate analyses, only tumor stage, not histology or overexpression of EGFR, TGF-alpha, or both, had a significant impact on overall survival. No expression of epidermal growth factor or cripto was observed at the total cellular RNA level of Northern analysis in tumor or benign lung, suggesting that in NSCLC these ligands may not participate in an autocrine growth stimulatory loop with EGFR. Differential overexpression of amphiregulin in malignant versus normal lung was observed, but this expression pattern did not have a prognostic impact. Thus, EGFR and TGF-alpha overexpression is frequent in early-stage NSCLC but is not associated with a survival difference. These findings suggest that this growth factor/receptor loop is more important for lung tumor formation than for tumor progression.


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
I. S. Sarkaria, M. F. Zakowski, D. Pham, M. Hezel, M. I. Ebright, S. Chuai, E. S. Venkatraman, M. G. Kris, V. W. Rusch, and B. Singh
Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components
Ann. Thorac. Surg., January 1, 2008; 85(1): 216 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Wu, M. S. O'Reilly, R. R. Langley, R. Z. Tsan, C. H. Baker, N. Bekele, X. M. Tang, A. Onn, I. J. Fidler, and R. S. Herbst
Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Mol. Cancer Ther., October 1, 2007; 6(10): 2652 - 2663.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, et al.
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3936 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA, July 4, 2007; 298(1): 70 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Adachi, T. Nagao, H. I. Ingolfsson, F. R. Maxfield, O. S. Andersen, L. Kopelovich, and I. B. Weinstein
The Inhibitory Effect of (-)-Epigallocatechin Gallate on Activation of the Epidermal Growth Factor Receptor Is Associated with Altered Lipid Order in HT29 Colon Cancer Cells
Cancer Res., July 1, 2007; 67(13): 6493 - 6501.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
K. Kitao, S. Yoshida, S. Kennedy, N. Takemura, M. Sugimoto, M. Deguchi, N. Ohara, and T. Maruo
Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Gene Polymorphisms in Endometrial Cancer in a Japanese Population
Reproductive Sciences, May 1, 2007; 14(4): 349 - 357.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Koyama, Y. Matsuzaki, S. Yogosawa, T. Hitomi, M. Kawanaka, and T. Sakai
ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
Mol. Cancer Ther., May 1, 2007; 6(5): 1579 - 1587.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Morgillo, W.-Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong, and H.-Y. Lee
Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib
Clin. Cancer Res., May 1, 2007; 13(9): 2795 - 2803.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Ma, S. Fiering, C. Black, X. Liu, Z. Yuan, V. A. Memoli, D. J. Robbins, H. A. Bentley, G. J. Tsongalis, E. Demidenko, et al.
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas
PNAS, March 6, 2007; 104(10): 4089 - 4094.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R Dziadziuszko, B Holm, B. Skov, K Osterlind, M. Sellers, W. Franklin, P. Bunn Jr, M Varella-Garcia, and F. Hirsch
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy
Ann. Onc., March 1, 2007; 18(3): 447 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Engelman and L. C. Cantley
The Role of the ErbB Family Members in Non-Small Cell "Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors".
Clin. Cancer Res., July 15, 2006; 12(14): 4372s - 4376s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Swanton, A. Futreal, and T. Eisen
Her2-targeted therapies in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4377s - 4383s.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Ettinger
Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non-Small Cell Lung Cancer.
Oncologist, April 1, 2006; 11(4): 358 - 373.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Sonnweber, M Dlaska, S Skvortsov, S Dirnhofer, T Schmid, and W Hilbe
High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).
J. Clin. Pathol., March 1, 2006; 59(3): 255 - 259.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Thorax, February 1, 2006; 61(2): 140 - 145.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Robert, G. Blumenschein, R. S. Herbst, F. V. Fossella, J. Tseng, M. N. Saleh, and M. Needle
Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naive Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9089 - 9096.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. A. Silvestri and M. P. Rivera
Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer: A Review of the Epidermal Growth Factor Receptor Antagonists
Chest, December 1, 2005; 128(6): 3975 - 3984.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Dutu, S. Michiels, P. Fouret, F. Penault-Llorca, P. Validire, S. Benhamou, E. Taranchon, L. Morat, D. Grunenwald, T. Le Chevalier, et al.
Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers
Ann. Onc., December 1, 2005; 16(12): 1906 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H.-Y. Lee, S.-H. Oh, J. K. Woo, W.-Y. Kim, C. S. Van Pelt, R. E. Price, D. Cody, H. Tran, J. M. Pezzuto, R. M. Moriarty, et al.
Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis
J Natl Cancer Inst, November 16, 2005; 97(22): 1695 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. M. Langenfeld, J. Bojnowski, J. Perone, and J. Langenfeld
Expression of Bone Morphogenetic Proteins in Human Lung Carcinomas
Ann. Thorac. Surg., September 1, 2005; 80(3): 1028 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Mukohara, J. A. Engelman, N. H. Hanna, B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, et al.
Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
J Natl Cancer Inst, August 17, 2005; 97(16): 1185 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-Y. Lee, S.-H. Oh, Y.-A. Suh, J. H. Baek, V. Papadimitrakopoulou, S. Huang, and W. K. Hong
Response of Non-Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 6065 - 6074.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, et al.
Erlotinib in Previously Treated Non-Small-Cell Lung Cancer
N. Engl. J. Med., July 14, 2005; 353(2): 123 - 132.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. S. Tsao, A. Sakurada, J.-C. Cutz, C.-Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, et al.
Erlotinib in Lung Cancer -- Molecular and Clinical Predictors of Outcome
N. Engl. J. Med., July 14, 2005; 353(2): 133 - 144.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura
Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer
Chest, July 1, 2005; 128(1): 308 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson
Development of strategies for the use of anti-growth factor treatments
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Hurbin, J.-L. Coll, L. Dubrez-Daloz, B. Mari, P. Auberger, C. Brambilla, and M.-C. Favrot
Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer Cells
J. Biol. Chem., May 20, 2005; 280(20): 19757 - 19767.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, J. A. Engelman, and B. E. Johnson
Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
J. Clin. Oncol., May 10, 2005; 23(14): 3227 - 3234.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, D. H. Johnson, E. Mininberg, D. P. Carbone, T. Henderson, E. S. Kim, G. Blumenschein Jr, J. J. Lee, D. D. Liu, M. T. Truong, et al.
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2544 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Yang, L. E. Mechanic, P. Yang, M. T. Landi, E. D. Bowman, J. Wampfler, D. Meerzaman, K. M. Hong, F. Mann, T. Dracheva, et al.
Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2005; 11(6): 2106 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Chest, March 1, 2005; 127(3): 978 - 983.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P. P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, et al.
EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
J. Clin. Oncol., February 1, 2005; 23(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Raben, B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Baron, C. Zeng, T. K. Johnson, and P. A. Bunn Jr
The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 795 - 805.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. J. Petty, K. H. Dragnev, V. A. Memoli, Y. Ma, N. B. Desai, A. Biddle, T. H. Davis, W. C. Nugent, N. Memoli, M. Hamilton, et al.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers
Clin. Cancer Res., November 15, 2004; 10(22): 7547 - 7554.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Pitha-Rowe, W. J. Petty, Q. Feng, P. H. Koza-Taylor, D. A. DiMattia, L. Pinder, K. H. Dragnev, N. Memoli, V. Memoli, T. Turi, et al.
Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention
Cancer Res., November 1, 2004; 64(21): 8109 - 8115.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non--Small-Cell Lung Cancer
J. Clin. Oncol., August 15, 2004; 22(16): 3238 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. V. Scagliotti, G. Selvaggi, S. Novello, and F. R. Hirsch
The Biology of Epidermal Growth Factor Receptor in Lung Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4227S - 4232S.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
A. S. Tsao, E. S. Kim, and W. K. Hong
Chemoprevention of Cancer
CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. A. Miller, M. G. Kris, N. Shah, J. Patel, C. Azzoli, J. Gomez, L. M. Krug, W. Pao, N. Rizvi, B. Pizzo, et al.
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 15, 2004; 22(6): 1103 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Perez-Soler
HER1/EGFR Targeting: Refining the Strategy
Oncologist, February 1, 2004; 9(1): 58 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Selvaggi, S. Novello, V. Torri, E. Leonardo, P. De Giuli, P. Borasio, C. Mossetti, F. Ardissone, P. Lausi, and G. V. Scagliotti
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
Ann. Onc., January 1, 2004; 15(1): 28 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
A. HURBIN, L. DUBREZ, J.-L. COLL, and M. C. FAVROT
Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor--Dependent Pathway in Non-Small Cell Lung Cancer Cell Lines
Ann. N.Y. Acad. Sci., December 1, 2003; 1010(1): 354 - 357.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch Jr, D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, et al.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer: A Randomized Trial
JAMA, October 22, 2003; 290(16): 2149 - 2158.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin
Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
J. Clin. Oncol., October 15, 2003; 21(20): 3798 - 3807.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W Hilbe, S Dirnhofer, F Oberwasserlechner, W Eisterer, K Ammann, T Schmid, G Hilbe, J Thaler, and E Woll
Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis
J. Clin. Pathol., October 1, 2003; 56(10): 736 - 741.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Sithanandam, G. T. Smith, A. Masuda, T. Takahashi, L. M. Anderson, and L. W. Fornwald
Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway
Carcinogenesis, October 1, 2003; 24(10): 1581 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cappuzzo, V. Gregorc, E. Rossi, A. Cancellieri, E. Magrini, C. T. Paties, G. Ceresoli, L. Lombardo, S. Bartolini, C. Calandri, et al.
Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
J. Clin. Oncol., July 15, 2003; 21(14): 2658 - 2663.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J.-Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, et al.
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., June 15, 2003; 21(12): 2237 - 2246.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. A. Miller, D. H. Johnson, L. M. Krug, B. Pizzo, L. Tyson, W. Perez, P. Krozely, A. Sandler, D. Carbone, R. T. Heelan, et al.
Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., June 1, 2003; 21(11): 2094 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone
Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways
Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Milas, R. Komaki, T. Hachiya, R. S. Bubb, J. Y. Ro, L. Langford, R. Sawaya, J. B. Putnam, P. Allen, J. D. Cox, et al.
Epidermal Growth Factor Receptor, Cyclooxygenase-2, and BAX Expression in the Primary Non-Small Cell Lung Cancer and Brain Metastases
Clin. Cancer Res., March 1, 2003; 9(3): 1070 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Brambilla, F. Fievet, M. Jeanmart, F. de Fraipont, S. Lantuejoul, V. Frappat, G. Ferretti, P.Y. Brichon, and D. Moro-Sibilot
Early detection of lung cancer: role of biomarkers
Eur. Respir. J., January 1, 2003; 21(39_suppl): 36S - 44s.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Hurbin, L. Dubrez, J.-L. Coll, and M.-C. Favrot
Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines
J. Biol. Chem., December 13, 2002; 277(51): 49127 - 49133.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
Eur. Respir. J., October 1, 2002; 20(4): 975 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. A. Janne, M. L. Taffaro, R. Salgia, and B. E. Johnson
Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma
Cancer Res., September 15, 2002; 62(18): 5242 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. S. Herbst and M. S. Kies
ZD1839 (IressaTM) in Non-Small Cell Lung Cancer
Oncologist, August 15, 2002; 7(90004): 9 - 15.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. L. Arteaga
Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?
Oncologist, August 15, 2002; 7(90004): 31 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page